Key Takeaways

• Histamine acts through four GPCR subtypes: H1, H2, H3 and H4.
• H1 drives allergy and is blocked by classic antihistamines; H2 controls gastric acid.
• H3 is a presynaptic autoreceptor in the brain; H4 modulates immune cell chemotaxis.
• Histamine is made by histidine decarboxylase (HDC) and broken down by histamine N-methyltransferase (HNMT).
• Antihistamines targeting H1 and H2 are among the most widely used drugs in the world.
• H3 and H4 are active areas of drug discovery for CNS and inflammatory disease.

Contents

• What Are Histamine Receptors?
• The Four Histamine Receptor Subtypes
• Histamine Synthesis & Breakdown
• Clinical Implications & Antihistamines
• Studying Histamine Receptors
• Frequently Asked Questions

Histamine Pathway ELISA Kits

Validated sandwich ELISA kits for all four histamine receptors and the two enzymes that control histamine levels.

HRH1

Histamine H1 Receptor ELISA Kit

Sandwich ELISARat

The allergy receptor — found on smooth muscle and endothelium, driving bronchoconstriction, itch and vasodilation.

View kit →

HRH2

Histamine H2 Receptor ELISA Kit

Sandwich ELISAHuman

Controls gastric acid secretion from parietal cells; the target of H2 blockers for ulcers and reflux.

View kit →

HRH3

Histamine H3 Receptor ELISA Kit

Sandwich ELISAHuman

A presynaptic autoreceptor in the CNS that regulates histamine and other neurotransmitter release.

View kit →

HRH4

Histamine H4 Receptor ELISA Kit

Sandwich ELISAHuman

Expressed on immune cells, mediating chemotaxis of mast cells, eosinophils and other leukocytes.

View kit →

HDC

Histidine Decarboxylase (HDC) ELISA Kit

Sandwich ELISAHuman

The rate-limiting enzyme that synthesises histamine from the amino acid histidine.

View kit →

HNMT

Histamine N-methyltransferase (HNMT) ELISA Kit

Sandwich ELISAHuman

The principal enzyme that inactivates histamine in the central nervous system and tissues.

View kit →

What Are Histamine Receptors?

Histamine is a biogenic amine that plays a crucial role in many physiological processes, including immune responses, gastric acid secretion and neurotransmission. It exerts these effects by binding to specific histamine receptors on the surface of target cells. All four receptors belong to the G protein-coupled receptor (GPCR) family, characterised by seven transmembrane domains that transduce an extracellular signal into an intracellular response.

To date, four subtypes have been identified — H1, H2, H3 and H4 — each with distinct signalling mechanisms, tissue distribution and downstream effects. This diversity is what allows a single small molecule, histamine, to trigger responses as different as a sneeze, a surge of stomach acid and the fine-tuning of neurotransmitter release. Understanding which receptor mediates which effect is the foundation of antihistamine pharmacology.

The Four Histamine Receptor Subtypes

The four receptors differ in the G protein they couple to and therefore in the second messengers they raise or lower.

H1 receptor

The H1 receptor is widely expressed on smooth muscle, endothelium and the central nervous system. Coupling through Gq/11, it raises intracellular calcium to produce the classic allergic response: bronchoconstriction, increased vascular permeability, itch and wakefulness. It is the target of the familiar antihistamines used for hay fever and urticaria.

H2 receptor

The H2 receptor is best known for its role on gastric parietal cells, where it stimulates acid secretion via Gs and rising cyclic AMP. H2 antagonists such as ranitidine and famotidine revolutionised the treatment of peptic ulcers and reflux. H2 receptors also appear on cardiac muscle and immune cells.

H3 receptor

The H3 receptor is found mainly in the central nervous system, where it acts as a presynaptic autoreceptor. By coupling through Gi/o it inhibits the release of histamine and other neurotransmitters, positioning it as a target for disorders of sleep, cognition and attention.

H4 receptor

The most recently discovered subtype, the H4 receptor, is expressed predominantly on cells of haematopoietic origin. Also Gi/o-coupled, it mediates the chemotaxis of mast cells, eosinophils and other leukocytes, making it a promising target for inflammatory and autoimmune conditions.

Histamine Synthesis & Breakdown

Receptor signalling is only half the story; the amount of histamine available to act on those receptors is set by two enzymes. Histamine is synthesised from the amino acid histidine by histidine decarboxylase (HDC), the rate-limiting step, chiefly in mast cells, basophils, enterochromaffin-like cells and certain neurons.

Once released, histamine is rapidly inactivated. In the central nervous system and most tissues this is carried out by histamine N-methyltransferase (HNMT), while diamine oxidase degrades histamine in the gut and other peripheral sites. Measuring HDC and HNMT alongside the receptors gives a complete picture of histaminergic tone in a tissue or disease model.

Clinical Implications & Antihistamines

The broad involvement of histamine receptors in physiological and pathological processes makes them attractive targets for therapeutic intervention. Antihistamines, which block the action of histamine at its receptors, are among the most widely used medicines in the world. H1 antagonists treat allergies, urticaria and, in their sedating first-generation form, insomnia; H2 antagonists reduce gastric acid in ulcers and reflux.

Drug discovery has since moved to the newer subtypes. H3 antagonists are being developed for narcolepsy, cognitive disorders and attention deficits, while H4 antagonists are in trials for asthma, atopic dermatitis and other inflammatory conditions. Because each subtype couples to a different pathway, selective agonists and antagonists can fine-tune histamine signalling without the off-target effects of earlier, non-selective drugs.